DMS Group Reports Q1 2026 Revenue of €10 Million Amid Market Challenges

Diagnostic Medical Systems (DMS), a leader in high-performance medical imaging, reported a revenue of €10 million for Q1 2026, marking an 8% decline compared to the same period in 2025. This downturn comes after a record Q4 2025, with predictions of a recovery in Q2 2026 owing to expected growth reboot.

Revenue from the Radiology division reached €8.1 million, a 5% dip, while Bone Densitometry saw a 20% drop to €1.9 million. The 1st quarter's decrease is seen as temporary, with a shift towards increased own-brand sales against OEM agreements.

Geographically, DMS capitalized on international markets such as Africa and South America, while experiencing a slight fall in North America and Europe. Despite regional challenges, DMS is optimistic about leveraging international sales for growth in 2026.